Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for the stock's performance in the near term [6]. Core Insights - The company is expected to achieve revenue of $370.28 million in FY2025, representing a growth of 37.8%, and a net profit of $26.33 million, reflecting a significant increase of 162.8% [2]. - The domestic market is projected to see a case number increase of 26.3% to 276,200 cases, while the overseas market is anticipated to grow by 82.1% to 256,200 cases, indicating strong performance in both segments [2]. - The company is focusing on cost reduction and efficiency improvements in production and design, which is expected to enhance profitability in the domestic market [4]. - The overseas market is expected to achieve a breakeven point in the second half of 2026, with significant growth potential and improved profit margins anticipated [4]. Financial Summary - For FY2025, the company is projected to generate total revenue of $370 million, with a year-on-year growth rate of 37.8% [5]. - The net profit attributable to the parent company is expected to be $28.44 million in FY2026, with a growth rate of 134.7% [5]. - The earnings per share (EPS) is forecasted to be $0.17 in FY2025, with a projected increase to $0.33 by FY2028 [5]. - The company has a strong cash reserve of $48.8 million, which supports its dividend policy aiming for a payout ratio of 40% of net profit [3].
时代天使（06699）：年报业绩点评：国内案例数高增，海外大幅减亏，前景持续向好